dhbuzz Thursday, 10/03/19 02:00:58 PM Re: dhbuzz post# 1976 Post # of 2106 Professor Sadleir says the product offers new hope for children and adolescents experiencing severe epileptic seizures, who currently have few effective options for treatment. The phase II clinical trial assessed the product's safety and efficacy in children and adolescents with Developmental and Epileptic Encephalopathies. These are the most difficult to treat epilepsies, and include the conditions Dravet Syndrome and Lennox-Gastaut syndrome. Patients with Developmental and Epileptic Encephalopathy have frequent severe seizures as well as severe cognitive and behavioral impairment. Professor Sadleir says the gel not only reduced the number of epileptic seizures the children had, but also led to a reported improvement in behavioral and cognitive symptoms. It was also very well tolerated. "These conditions are the most challenging and poorly controlled of all epilepsy disorders, and have a tremendous impact on the families involved.